185 related articles for article (PubMed ID: 1417721)
1. [Formal pathogenesis, average age and breed distribution in the comparison of 61 Lysodren-treated and 36 untreated cases of canine hyperadrenocorticism which were dissected in the years 1975 to 1991 at the Institute for Veterinary Pathology of the Free University of Berlin].
Nothelfer HB; Weinhold K
Berl Munch Tierarztl Wochenschr; 1992 Sep; 105(9):305-11. PubMed ID: 1417721
[TBL] [Abstract][Full Text] [Related]
2. Problems associated with medical therapy of canine hyperadrenocorticism.
Nichols R
Probl Vet Med; 1990 Dec; 2(4):551-6. PubMed ID: 2134073
[TBL] [Abstract][Full Text] [Related]
3. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs.
Feldman EC; Nelson RW; Feldman MS; Farver TB
J Am Vet Med Assoc; 1992 Jun; 200(11):1642-7. PubMed ID: 1320600
[TBL] [Abstract][Full Text] [Related]
4. [Familial canine pituitary-dependent hyperadrenocorticism in wirehaired Dachshunds].
Stritzel S; Mischke R; Philipp U; Kleinschmidt S; Wohlsein P; Stock KF; Distl O
Berl Munch Tierarztl Wochenschr; 2008; 121(9-10):349-58. PubMed ID: 18822606
[TBL] [Abstract][Full Text] [Related]
5. [Laboratory parameters for the control of the course of therapy of canine Cushing's syndrome].
Reusch C; Hähnle B
Tierarztl Prax; 1991 Feb; 19(1):102-6. PubMed ID: 1646492
[TBL] [Abstract][Full Text] [Related]
6. Plasma cortisol response to ketoconazole administration in dogs with hyperadrenocorticism.
Feldman EC; Bruyette DS; Nelson RW; Farver TB
J Am Vet Med Assoc; 1990 Jul; 197(1):71-8. PubMed ID: 2370223
[TBL] [Abstract][Full Text] [Related]
7. Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism.
Clemente M; De Andrés PJ; Arenas C; Melián C; Morales M; Pérez-Alenza MD
Vet Rec; 2007 Dec; 161(24):805-9. PubMed ID: 18083978
[TBL] [Abstract][Full Text] [Related]
8. [Experiences with Lysodren therapy of Cushing's syndrome in the dog (1)].
Opitz M; Lettow E; Loppnow H; Grevel V
Tierarztl Prax; 1983; 11(3):369-84. PubMed ID: 6636131
[No Abstract] [Full Text] [Related]
9. Pituitary macroadenomas and macroadenocarcinomas in dogs treated with mitotane for pituitary-dependent hyperadrenocorticism: 13 cases (1981-1986).
Nelson RW; Ihle SL; Feldman EC
J Am Vet Med Assoc; 1989 Jun; 194(11):1612-7. PubMed ID: 2753785
[TBL] [Abstract][Full Text] [Related]
10. Mitotane treatment of 32 dogs with cortisol-secreting adrenocortical neoplasms.
Kintzer PP; Peterson ME
J Am Vet Med Assoc; 1994 Jul; 205(1):54-61. PubMed ID: 7928549
[TBL] [Abstract][Full Text] [Related]
11. Hyperadrenocorticism: treating dogs.
Brown CG; Graves TK
Compend Contin Educ Vet; 2007 Mar; 29(3):132-4, 136, 138 passim; quiz 144-5. PubMed ID: 17726933
[TBL] [Abstract][Full Text] [Related]
12. [Experiences with Lysodren treatment of Cushing's syndrome in dogs].
Opitz M; Lettow E; Loppnow H; Grevel V
Tierarztl Prax; 1983; 11(4):507-20. PubMed ID: 6658774
[No Abstract] [Full Text] [Related]
13. Hyperadrenocorticism caused by bilateral adrenocortical neoplasia in dogs: four cases (1983-1988).
Ford SL; Feldman EC; Nelson RW
J Am Vet Med Assoc; 1993 Mar; 202(5):789-92. PubMed ID: 8454518
[TBL] [Abstract][Full Text] [Related]
14. Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane.
Reine NJ
Clin Tech Small Anim Pract; 2007 Feb; 22(1):18-25. PubMed ID: 17542193
[TBL] [Abstract][Full Text] [Related]
15. Use of the urine cortisol-to-creatinine ratio for monitoring dogs with pituitary-dependent hyperadrenocorticism during induction treatment with mitotane (o,p'-DDD).
Randolph JF; Toomey J; Center SA; Scarlett JM; Reimers T; Graham P; Nachreiner RF
Am J Vet Res; 1998 Mar; 59(3):258-61. PubMed ID: 9522940
[TBL] [Abstract][Full Text] [Related]
16. Distinguishing dogs with functioning adrenocortical tumors from dogs with pituitary-dependent hyperadrenocorticism.
Feldman EC
J Am Vet Med Assoc; 1983 Jul; 183(2):195-200. PubMed ID: 6309721
[No Abstract] [Full Text] [Related]
17. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane.
Helm JR; McLauchlan G; Boden LA; Frowde PE; Collings AJ; Tebb AJ; Elwood CM; Herrtage ME; Parkin TD; Ramsey IK
J Vet Intern Med; 2011; 25(2):251-60. PubMed ID: 21352377
[TBL] [Abstract][Full Text] [Related]
18. Canine hyperadrenocorticism: pretreatment clinical and laboratory evaluation of 117 cases.
Ling GV; Stabenfeldt GH; Comer KM; Gribble DH; Schechter RD
J Am Vet Med Assoc; 1979 Jun; 174(11):1211-5. PubMed ID: 438050
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hyperadrenocorticism in dogs: a survey of internists and dermatologists.
Behrend EN; Kemppainen RJ; Clark TP; Salman MD; Peterson ME
J Am Vet Med Assoc; 1999 Oct; 215(7):938-43. PubMed ID: 10511856
[No Abstract] [Full Text] [Related]
20. One-year follow-up evaluation of magnetic resonance imaging of the brain in dogs with pituitary-dependent hyperadrenocorticism.
Bertoy EH; Feldman EC; Nelson RW; Dublin AB; Reid MH; Feldman MS
J Am Vet Med Assoc; 1996 Apr; 208(8):1268-73. PubMed ID: 8635969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
